Identification of ezetimibe and pranlukast as pharmacological

Article Cite This: J. Med. Chem. 2019, 62, 6175−6189

pubs.acs.org/jmc

Identification of Ezetimibe and Pranlukast as Pharmacological Chaperones for the Treatment of the Rare Disease Mucopolysaccharidosis Type IVA

Downloaded via NOTTINGHAM TRENT UNIV on July 18, 2019 at 15:52:00 (UTC). See https://pubs.acs.org/sharingguidelines for options on how to legitimately share published articles.

Carlos J. Alméciga-Diaz,*,† Oscar A. Hidalgo,† Sergio Olarte-Avellaneda,†,‡ Alexander Rodríguez-López,†,§ Esteban Guzman,† Rafael Garzón,† Luisa Natalia Pimentel-Vera,† María Alejandra Puentes-Tellez,† Andrés Felipe Rojas-Rodriguez,∥ Kirill Gorshkov,⊥ Rong Li,⊥ and Wei Zheng*,⊥ †

Institute for the Study of Inborn Errors of Metabolism, Faculty of Science, §Chemistry Department, Faculty of Science, and Computational and Structural Biochemistry, Departamento de Nutrición y Bioquímica, Faculty of Science, Pontificia Universidad Javeriana, Bogotá D.C. 110231, Colombia ‡ Pharmacy Department, Faculty of Science, Universidad Nacional de Colombia, Bogotá D.C. 111321, Colombia ⊥ National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, Maryland 20892, United States ∥

S Supporting Information *

ABSTRACT: Mucopolysaccharidosis type IVA (MPS IVA) is a rare disease caused by mutations in the gene encoding the lysosomal enzyme N-acetylgalactosamine-6-sulfate sulfatase (GALNS). We report here two GALNS pharmacological chaperones, ezetimibe and pranlukast, identified by molecular docking-based virtual screening. These compounds bound to the active cavity of GALNS and increased its thermal stability as well as the production of recombinant GALNS in bacteria, yeast, and HEK293 cells. MPS IVA fibroblasts treated with these chaperones exhibited increases in GALNS protein and enzyme activity and reduced the size of enlarged lysosomes. Abnormalities in autophagy markers p62 and LC3B-II were alleviated by ezetimibe and pranlukast. Combined treatment of recombinant GALNS with ezetimibe or pranlukast produced an additive effect. Altogether, the results demonstrate that ezetimibe and pranlukast can increase the yield of recombinant GALNS and be used as a monotherapy or combination therapy to improve the therapeutic efficacy of MPS IVA enzyme replacement therapy.

1. INTRODUCTION Mucopolysaccharidosis type IVA (MPS IVA, OMIM 253000), also called Morquio A syndrome, is a lysosomal storage disease (LSD) caused by mutations in the gene encoding for the enzyme N-acetylgalactosamine-6-sulfate sulfatase (GALNS, EC 3.1.6.4).1 Worldwide incidence rates of MPS IVA range from 0.14 to 0.009 (per 10 000 at birth).2 GALNS deficiency leads to the lysosomal accumulation of the glycosaminoglycans (GAGs), keratan sulfate (KS) and chondroitin-6-sulfate (C6S).1,3 Treatment options for MPS IVA patients currently include nonsteroidal anti-inflammatory drugs, antibiotics, oxygen supplementation, surgical procedures to correct orthopedic deformities and tracheal obstructions, enzyme replacement therapy (ERT), and hematopoietic stem cell transplantation (HSCT).1,3,4 Patients under ERT with elosulfase alfa have shown some improvements in clinical symptoms of the disease.5 A weekly intravenous administration of 2.0 mg/kg for 24 weeks produced a slight improvement in the 6 min walk test and the reduction of urinary KS6 in the phase III studies, as well as an improvement in the maximal voluntary ventilation, performance of daily life activities, and height/growth rate.7 Unfortunately, ERT has limited effects in © 2019 American Chemical Society

correcting the skeletal, corneal, and cardiac abnormalities because of tissue avascularity and short half-life of the enzyme.5 A recent study showed that MPS IVA ERT-treated patients continue to exhibit poor growth despite early ERT intervention before 5 years of age. These findings indicate that current intravenous ERT is ineffective at correcting abnormal growth in MPS IVA.8 In addition, all MPS IVAtreated patients developed antidrug antibodies at week 120, although antibody titers did not correlate with clinical efficacy or adverse effects.9 Treating MPS IVA patients with HSCT is relatively new, and recent studies have shown long-term and normal enzyme activities, increase in lumbar bone mineral density, improvement in ambulatory movement, and remission of the narrow airway.10−12 Nevertheless, HSCT is a high-risk procedure with many possible complications and high mortality. Limitations of current therapies indicate an unmet need for new therapeutic strategies to improve and expand the treatment options for MPS IVA patients. Received: March 11, 2019 Published: June 12, 2019 6175

DOI: 10.1021/acs.jmedchem.9b00428 J. Med. Chem. 2019, 62, 6175−6189

Journal of Medicinal Chemistry

Article

Figure 1. (A) Structures of ezetimibe and pranlukast. (B) In silico molecular docking of C6S (orange), KS (green), 4-methylumbelliferyl-β-Dgalactopyranoside-6-sulfate (red), ezetimibe (purple), and pranlukast (blue) within the active site cavity of human GALNS. Catalytic residue (C79) and calcium ion from GALNS are shown. The GALNS tertiary structure, previously reported,20 was modeled by using the human arylsulfatase A (PDB 1AUK) as a template for protein threading. (C) Hydrogen bond interactions between GALNS and ligands.

activity of the mutant proteins in a mutation-dependent manner, which may be sufficient to ameliorate most disease symptoms,23,27 suggesting that chaperones could be employed as a monotherapy. In addition, it has been observed that these drugs can enhance the stability of recombinant lysosomal enzymes, suggesting that coadministration of a pharmacological chaperone and the enzyme may increase the efficacy of the ERT.21,22 Previously, we reported computational docking for natural (KS and C6S) and artificial (4-methylumbelliferyl-β-Dgalactopyranoside-6-sulfate, 4MUGPS) ligands of human GALNS.20 Here, we describe the characterization of two pharmacological chaperones for GALNS identified from a molecular docking-based virtual screening against a library of experimental and approved drugs. Our data indicated that these compounds bind to the active cavity of GALNS, increasing the activity and thermostability of human recombinant GALNS (hrGALNS). These molecules reduced the lysosomal mass and normalized the abnormal autophagic processes in MPS IVA patient-derived fibroblasts. Therefore, these novel pharmacological chaperones have potential for further drug development to improve the treatment and outcomes for patients suffering from MPS IVA. The benefit of using the chaperones can be realized in three aspects: an increase in the production of proteins for ERT, as a monotherapy for MPS IVA patients, and combined with ERT to improve the efficacy of therapy.

GALNS protein is a 120 kDa homodimer with two 60 kDa monomers composed of 40 and 15 kDa polypeptides connected by disulfide bonds and modified by two Nglycosylations.13,14 Currently, over 217 deleterious mutations have been reported in the GALNS gene, including missense/ nonsense (73%), minor mutations of splicing (9%), small deletions (10%), small insertions (2%), small indels (1%), gross deletions (2%), gross insertions/duplications (1%), and complex rearrangements (1%).15 GALNS genotype−phenotype correlations have predicted mutations that may affect the hydrophobic core, salt bridges, ligand affinity, solventaccessible surface, and N-glycosylation sites.14,16−20 On the basis of these findings, pharmacological chaperones have been proposed as treatment alternative for MPS IVA.1 Pharmacological chaperones are small molecules that bind to the target protein at the endoplasmic reticulum. These molecules usually serve as molecular templates that stabilize the native conformation of a protein or promote the correct folding and trafficking of a mutant protein.21,22 Pharmacological chaperones usually bind to the active site of a protein at a concentration below 10 μM23−25 and increase its the thermal stability.24 Compared to ERT, pharmacological chaperones have advantages of oral administration, wide tissue distribution profile, and fewer issues of immunogenicity.24,25 In LSD, pharmacological chaperones have been experimentally tested on Fabry disease with 1-deoxygalactonojirimycin (migalastat),26 as well as Gaucher disease, Pompe disease, and gangliosidosis (GM1 and GM2).27,28 For MPS, pharmacological chaperones have been studied for MPS II,29 MPS IIIC,28 and MPS IVB30 but not yet for MPS IVA. Overall, it has been observed that these molecules increase the enzyme

2. RESULTS 2.1. Virtual Screening Identified Small-Molecule Binders of Human GALNS. We have previously reported 6176



Article

that docking of human GALNS with different substrates suggested the importance of Asp39, Asp40, formylglycine (FGly) 79, Arg83, Tyr108, His142, His236, Asp288, Asn289, and Lys310 in protein−ligand interactions.20 The modeled GALNS has high similarity to the reported crystal structure of human GALNS [root-mean-squared distance (rmsd) of 1.2 Å] with the main differences observed in regions further from the active site cavity.20 These results, in addition to other structure and docking results,31 suggest that the modeled GALNS structure can be used to identify small molecules interacting with the active site cavity of the enzyme. In this study, we used the modeled structure of GALNS and performed a virtual screening that identified a set of compounds. Among the top 20 interacting compounds (Supporting Information, Table S1), the antibiotic, antineoplastic, antiestrogen, antiviral, and epigenetic regulator compounds were not considered for further investigation because of the intended use for the treatment of pediatric patients and the potential side effects of long-term administration. Ezetimibe (ZINC3810860) and pranlukast (ZINC22001688) ranked third and fourth, respectively, among the 11 421 compounds present in the ZINC In Man subset from ZINC (a free public resource for ligand discovery in silico) and were selected for further analysis (Figure 1A). In silico simulations showed that ezetimibe and pranlukast docked in the active cavity of GALNS in a similar position to that predicted for natural and artificial substrates of the enzyme (Figure 1B). Docking results predicted that ezetimibe and pranlukast also interact with some of the amino acids predicted for the natural (KS and C6S) and the artificial (4MUGPS) substrates (Figures 1C and S1). The Ca2+ ion present in the active cavity has been proposed as a cofactor for the GALNS enzyme and the interaction of a substrate with Ca2+ has been proposed to be required for enzyme activity.14,20 It is noteworthy that docking results also predicted an interaction of ezetimibe with Ca2+ present within the active cavity. Molecular dynamics simulations showed that GALNS substrates (KS, C6S, and 4MUGPS) and the selected small molecules (ezetimibe and pranlukast) were stable within the active cavity during the simulation (Figure 2A). In addition, both ezetimibe (−41.19 ± 0.028 kJ/mol) and pranlukast (−58.15 ± 0.024 kJ/mol) showed higher Gibbs free energy of binding (meaning a lower binding affinity) than that observed for the enzyme substrates (KS: −112.75 ± 0.049 kJ/mol, CS: −84.70 ± 0.082 kJ/mol, and 4MUGPS: −91.60 ± 0.073 kJ/ mol) (Figure 2B). These results suggest that ezetimibe and pranlukast may be weak competitors of the enzyme substrates, KS and C6S, for GALNS in lysosomes. These data are consistent with the characteristics of a pharmacological chaperone, which often acts as a mild competitor with enzyme substrates. 2.2. Ezetimibe and Pranlukast Weakly Inhibited GALNS Activity and Increased Its Thermal Stability. Previously, we reported the characterization of hrGALNS produced in the yeast Pichia pastoris.32,33 This enzyme showed similar posttranslational processing as GALNS from human leucocytes with the maximum activity at pH 5.0 and a stability profile similar to that of hrGALNS produced in CHO cells.32,33 Both ezetimibe and pranlukast inhibited the enzyme activity of hrGALNS by 40−50% at a concentration of 10 μM (Figure 3A). In a thermal shift experiment, both ezetimibe and pranlukast increased the thermal stability of hrGALNS by approximately 5 °C (Figure 3B). Together, the results revealed

Figure 2. Molecular dynamics simulation for GALNS and ligands. Molecular dynamics simulations were carried out for 20 ns using GROMAC 4.5.5. The trajectories were analyzed by rmsd (A) and the affinity energy (B). KS: keratan sulfate, C6S: chondroitin-6-sulfate, 4MUGPS: 4-methylumbelliferyl-β-D-galactopyranoside-6-sulfate.

Figure 3. Effects of ezetimibe and pranlukast on enzyme activity and thermal stability of hrGALNS. (A) Recombinant GALNS was incubated with the fluorogenic substrate 4-methylumbelliferyl-β-Dgalactopyranoside-6-sulfate with or without ezetimibe or pranlukast. The GALNS activity was measured after an 18 h incubation as described in the Experimental Section. The results are reported as the percentage of activity relative to the results observed without ezetimibe or pranlukast. (B) Thermal stability was carried out by the thermal shift assay. hrGALNS was incubated with or without ezetimibe or pranlukast. The Tm was calculated by plotting the first derivative of the fluorescence emission as a function of temperature (−dF/dT). All assays were performed in triplicate.

that ezetimibe and pranlukast are direct binders and weak inhibitors of GALNS and thus may function as GALNS pharmacological chaperones. 2.3. Ezetimibe and Pranlukast Increased the Production of Recombinant GALNS. Protein folding represents an 6177



Article

production of hrGALNS in P. pastoris at the bioreactor scale (Figure S2). In the mammalian expression system with the plasmid pCXN-GALNS,39 the transfected HEK293 cells showed a 9.3and 10-fold increase in the intracellular and extracellular GALNS activity, respectively (Figure 5A). Treatment of 0.01 μM ezetimibe did not increase the intracellular GALNS activity but induced a slight increase in the extracellular activity (1.16fold), whereas treatment of 0.001 μM ezetimibe produced a marked increase in GALNS activity both intra- (1.5-fold) and extracellularly (1.6-fold). On the other hand, the treatment with 0.01 and 0.001 μM pranlukast produced a 1.4- and 1.3fold increase in GALNS activity intracellularly, respectively, and 1.7- and 1.8-fold extracellularly, respectively (Figure 5A). Interestingly, cotreatment with ezetimibe and pranlukast did not induce any increase in GALNS activity at the extracellular fraction and had a negative effect in the intracellular GALNS, inducing a 1.5-fold reduction in enzyme activity. These results might be due to the additive inhibitory activity of the two compounds. Immunostaining showed increases in GALNS protein levels in the transfected HEK293 cells treated with these two compounds (Figure 5B). Together, the results indicated that ezetimibe and pranlukast could increase GALNS production in all three expression systems through the pharmacological chaperone activity by improving the proper folding and trafficking of newly synthesized GALNS proteins. 2.4. Ezetimibe and Pranlukast Acted as Pharmacological Chaperones in MPS IVA Patient-Derived Fibroblasts. The mutations in the MPS IVA fibroblasts were identified and confirmed as p.R61W, p.R94C, p.F285del, p.A393S, and p.W405_T406del (Table 1). All the fibroblasts, with the exception of GM00958 that is homozygous for the pA393S mutation, are heterozygous for missense mutations or amino acid deletions predicted as deleterious or damaging by at least one of the prediction tools. Bioinformatics analysis predicted that all mutations induced structural changes in the protein, as observed by changes in total energy and rmsd values that were more marked for the in-frame deletions p.F285del and p.W405_T406del (Table 2). Molecular docking against KS, C6S, and 4MUGPS predicted that mutations p.F285del and p.W405_T406del significantly changed the affinity energies for all of the evaluated substrates (Table 3), suggesting that the structural changes caused by these mutations may affect the protein−ligand interactions. For the remaining mutations, reductions in ligand affinity were observed for two of the three evaluated ligands, with C6S showing the most marked reductions. Overall, these results show that the MPS IVA fibroblasts produce mutated GALNS susceptible to be treated by pharmacological chaperones. As shown in Figure 6A, all evaluated patient fibroblasts had reduced the GALNS enzyme activity ranging from 20 to 64% of the wild-type (WT) level. There was no clear genotype− phenotype correlation, as previously reported.16,20 In addition, western blot analysis showed reduced GALNS levels in all the patient fibroblasts (Figure 6B). Ezetimibe treatment significantly increased the GALNS activity by 1.6-, 1.4-, 2.5-, and 2.5fold in the GM01361, GM01259, GM00958, and GM00593 fibroblasts compared to DMSO-treated cells, respectively (Figure 6A). With 0.001 μM ezetimibe treatment, the GALNS activity in GM01259 patient fibroblasts equaled that of WT fibroblasts. Western blot analysis showed that 0.01 or 0.001 μM ezetimibe treatment significantly increased the GALNS protein levels in all the MPS IVA fibroblasts (Figure

important bottleneck in the production of recombinant proteins. Misfolded proteins not only reduce a protein’s biological activity but also trigger cellular stress, which results in low production yields.34,35 We previously demonstrated that improvement of protein folding significantly increased GALNS activity.36 In this sense, we hypothesized that ezetimibe and pranlukast may improve the proper folding of hrGALNS because of their pharmacological chaperone activity. Hence, we evaluated the effects of ezetimibe and pranlukast on production of hrGALNS in Escherichia coli BL21(DE3), P. pastoris GS115, and HEK293 cells by a measurement of GALNS activity in cultures. In the E. coli BL21(DE3) expression system, hrGALNS is detected in both the intra- and extracellular fractions.36−38 After addition of ezetimibe or pranlukast to E. coli BL21(DE3) cultures, the GALNS activity in the intracellular fraction was not changed. In the extracellular fraction, the GALNS activity was increased up to 1.3- and 1.7-fold (p < 0.001), compared to dimethyl sulfoxide (DMSO)-treated cultures, in the presence of ezetimibe and pranlukast, respectively, as seen in Figure 4A.

Figure 4. (A) Effect of ezetimibe and pranlukast on the production of hrGALNS in E. coli. The enzyme activity was measured in the soluble fraction of the cell lysate after a 24 h induction. No effect of ezetimibe and pranlukast on GALNS activity was observed in the extracellular fraction. Results are reported as relative to those observed in the control (DMSO alone)-treated cultures. (B) Effect of ezetimibe and pranlukast (0.001 μM) on the production of hrGALNS in the yeast P. pastoris. The GALNS activity was measured in the extracellular fractions at 24, 48, 72, and 96 h. No effect on GALNS activity was observed at higher concentrations of ezetimibe and pranlukast. The DMSO-treated cultures were used as the control groups (n = 3, ANOVA Sidak t-test **p < 0.01, ***p < 0.001, ****p < 0.0001).

In the P. pastoris expression system, hrGALNS was detected in the extracellular fraction because of the presence of a secretion signal peptide.32 The addition of 0.001 μM ezetimibe or pranlukast every 24 h in the culture led to an increase of up to 5.0-fold of GALNS activity compared with DMSO-treated cultures (Figure 4B). The highest enzyme activity in the culture was observed after 48 h incubation with ezetimibe (p < 0.0001), compared to that enzyme activity in the control culture at 72 h. Similar results were observed during the 6178



Article

Figure 5. Effect of ezetimibe and pranlukast on the production of recombinant GALNS in HEK293 cells. The cells were transfected with plasmid pCXN-GALNS and treated with different concentrations of ezetimibe and pranlukast. (A) Enzyme activities were measured in the cell lysates (intracellular) and culture media (extracellular) after compound treatments. DMSO-treated cells were used as control (n = 3, ANOVA Sidak t-test *p < 0.05, ****p < 0.0001). (B) HEK293 overexpressing human GALNS was immunostained to analyze the effect of pharmacological chaperones on the intracellular trafficking of hrGALNS. After 48 h treatment, cells were stained with LysoTracker Green DND-26 and GALNS was detected with a rabbit polyclonal anti-GALNS antibody. Scale bar = 20 μm.

Table 1. Prediction Analysis of MPS IVA Fibroblasts Used for Evaluating Ezetimibe and Pranlukasta prediction Tool Coriell ID

mutation

PolyPhen-2

PROVEAN

SIFT

GM00593

p.R386C p.F285del p.A393S p.R94C p.A393S p.R61W p.W405_T406del

probably damaging N.A. benign probably damaging benign probably damaging N.A.

deleterious deleterious neutral deleterious neutral deleterious deleterious

damaging N.A. damaging damaging damaging damaging N.A.

GM00958 GM01259 GM01361 a

Fibroblasts were obtained from Coriell Institute. N.A., not applicable.

Table 2. Bioinformatics Analysis of WT and Mutated GALNS

Table 3. Molecular Docking Analysis of WT and Mutant GALNS against Natural (KS and C6S) and Artificial (4MUGPS) Substrate

rmsd (Å)

protein WT p.R61W p.R94C p.F285del p.R386C p.A393S p.W405_T406del

total energy (kJ/mol) −22914.273 −22408.814 −22492.967 −20120.439 −22399.646 −22690.773 −20905.438

Δ energy vs wild-type (kJ/mol) −505.5 −421.3 −2793.8 −514.6 −223.5 −2008.8

affinity energy (kcal/mol) backbone 0.043 0.043 0.212 0.043 0.043 0.195

all atoms 0.051 0.051 0.317 0.051 0.050 0.284

6B). Pranlukast treatment produced an increase in GALNS activity in GM01361 (p.R61W/p.W405_T406del) and GM00958 (p.A393S) patient fibroblasts, albeit less effectively

protein

KS

C6S

4MUGPS

WT p.R61W p.R94C p.F285del p.R386C p.A393S p.W405_T406del

90.1 78.0 87.5 81.9 91.9 122.8 81.7

128.6 81.5 104.5 53.5 106.0 131.4 64.5

76.9 128.1 76.3 66.8 77.2 77.8 45.6

than ezetimibe (Figure 6A). Western blot results showed that treatment with pranlukast significantly increased the GALNS 6179



Article

Figure 6. Effects of pharmacological chaperone compounds on GALNS enzyme activity. (A) Effect of ezetimibe and pranlukast on GALNS activity in MPS IVA patient fibroblasts. The fibroblasts were treated with different concentrations of ezetimibe and pranlukast for 48 h, after which the GALNS activity was measured in the cell lysate. Dotted line corresponds to WT activity levels. All assays were performed in triplicate (ANOVA Sidak t-test *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001). (B) Effect of ezetimibe (Eze) and pranlukast (Pran) on GALNS protein levels as determined by western blot analysis. The fibroblasts were treated with different concentrations of ezetimibe and pranlukast for 48 h, after which the protein lysates from the fibroblasts were analyzed. The densities of specific bands were calculated by using NIH ImageJ 1.8.0. GALNS protein levels were normalized against β-actin density and reported as fold-change to WT levels (dotted line). All assays were performed in triplicate.

protein levels in all the evaluated patient fibroblasts (Figure 6B). 2.5. Lysosomal mass increased in patient-derived fibroblasts is ameliorated in ezetimibe- and pranlukasttreated cells. LysoTracker staining, a phenotypic assay that detects enlarged lysosomes and acidic organelles,40,41 exhibited 1.2- to 2.4-fold increases in MPS IVA patient cells, indicating significant increases in lysosomal mass compared to WT fibroblasts (Figure 7). The LysoTracker staining was dosedependently reduced in all the disease fibroblast lines after the ezetimibe treatment, demonstrating the reduction in enlarged lysosome mass (Figure 7A). In this sense, this study shows, for the first time, that this phenotypic assay can be used for drug screening in MPS IVA patient-derived cells. In addition, the data from Figures 6 and 7 suggest that the ezetimibe treatment significantly increased the GALNS protein levels and activity in the MPS IVA patient cells, resulting in reduction of the enlarged lysosome mass. Results with pranlukast were slightly different wherein LysoTracker staining did not change in

patient fibroblasts treated with pranlukast (Figure 7B). Together with information from Figure 6, these results suggest that pranlukast might increase the stability of the enzyme but not its proper folding, thus limiting the recovery of the function of the mutated enzymes. 2.6. Abnormal Autophagy Markers in the MPS IVA Patient Fibroblasts Were Ameliorated by Ezetimibe and Pranlukast. Prior to this study, the autophagy markers p62 and LC3B-II in MPS IVA cells have not been reported. We found a significant reduction of p62 levels in all MPS IVA cells and decrease in LC3B-II levels in the GM01259, GM00958, and GM00593 fibroblasts, as shown in Figure 8. The results suggested that autophagic processes might be disrupted in patient cells. To further evaluate the therapeutic potential of ezetimibe and pranlukast, we measured the changes in p62 and LC3B-II levels after treatment with these two pharmacological chaperones. The treatments of MPS IVA fibroblasts with ezetimibe and pranlukast at 0.01 and 0.001 μM concentrations, respectively, significantly increased the levels of 6180



Article

Figure 7. Effect of ezetimibe (A) or pranlukast (B) on the reduction of lysosome mass in MPS IVA patient fibroblasts. Cells were treated with ezetimibe or pranlukast for 48 h, after which the cells were stained with the LysoTracker Red DND-99 dye. The images (9 images/well) were acquired using the IN Cell Analyzer 2200 imaging system. Results are presented as cell intensity normalized to the WT fluorescence level (dotted lines). All assays were performed in triplicate (ANOVA Sidak t-test *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001). Scale bar: 100 μm.

reduction of lysosomal mass and normalization of autophagic function. Treatment of MPS IVA cells with a combination of hrGALNS and ezetimibe (or pranlukast) significantly reduced the lysosomal accumulation phenotype in MSP IVA cells, suggesting an additive effect of the combination treatment. One type of pharmacological chaperone for LSDs emulates the structure of the enzyme’s substrate. For example, 1deoxynojirimycin-based, isofagomine-based, and 1,5-dideoxy1,5-imino-D-xylitol-based compounds act as pharmacological chaperones by binding to the active site of enzymes.24,25 In the case of MPS II, a sulfated disaccharide derived from heparin (Δ-unsaturated 2-sulfouronic acid-N-sulfoglucosamine) was reported as a pharmacological chaperone that mimics the structure of the natural substrate of iduronate-2-sulfatase (IDS).29 Nonsubstrate-like pharmacological chaperones have been described by Gaucher42,43 and Krabbe.44 Yilmazer et al.45 used a ligand-based and structure-based pharmacophore hypothesis for virtual screening of a ZINC database, resulting in the identification of chaperone compounds for βglucocerebrosidase that have tricyclic pyrido-thieno-pyrimidine or dioxino quinolone scaffolds and include antiallergic, antibiotic, and antineoplastic drugs. In the present study, molecular docking and virtual screening identified ezetimibe and pranlukast as potential pharmacological chaperones for human GALNS. Ezetimibe is an approved drug that blocks intestinal cholesterol absorption by selectively inhibiting Niemann−Pick C1-like 1 protein and is indicated for the treatment of disorders with elevated cholesterol levels.46 Pranlukast is an orally administered, selective and competitive cysteinyl leukotriene type 1 receptor antagonist, indicated for the treatment of bronchial asthma in pediatric and adult patients.47 In terms of safety, both ezetimibe and pranlukast are well tolerated and have adverse event profiles similar to

p62 and LC3B-II as seen in Figure 8. Higher increases in p62 levels were observed in the ezetimibe-treated cells than the increased levels in the pranlukast-treated cells. 2.7. Combination Therapy of ERT with the Pharmacological Chaperone. We previously found that the cellular uptake of hrGALNS produced in P. pastoris is mediated by both mannose and mannose-6-phosphate receptors and targeted to the lysosome.32,33 To evaluate the effect of the two pharmacological chaperones on ERT, we coadministrated the hrGALNS enzyme with ezetimibe or pranlukast in the MPS IVA fibroblasts. As shown in Figure 9, the combination treatment of patient cells with hrGALNS and a pharmacological chaperone (ezetimibe or pranlukast) further decreased LysoTracker staining compared to those treated only with hrGALNS, indicating an additive effect with further reduction of lysosomal mass in the patient cells. The combination therapy with hrGALNS and pranlukast almost normalized the LysoTracker staining in all MPS IVA fibroblasts to the levels in WT control cells, although pranlukast did not reduce lysosomal mass when it was used by itself. Together, the results suggested that the combination therapy of ERT with ezetimibe or pranlukast might improve the clinical efficacy of ERT in MPS IVA patients.

3. DISCUSSION In this study, we describe, for the first time, two small molecules (ezetimibe and pranlukast) with pharmacological chaperone activity for GALNS. These two molecules bind to the active cavity of GALNS and act as chaperones by stabilizing the protein structure. They increased the production of hrGALNS in E. coli, P. pastoris, and HEK293 cells. In addition, ezetimibe treatment increased the activity and protein level of GALNS in MPS IVA fibroblasts, leading to a 6181



Article

Figure 8. Evaluation of the autophagy markers p62 and LC3B-II in MPS IVA fibroblasts treated with ezetimibe (A) or pranlukast (B). The fibroblasts were treated with different concentrations of the pharmacological chaperones for 48 h, after which the protein was analyzed in the cell lysates. The densities of specific bands were calculated by using NIH ImageJ 1.8.0. Results were normalized against β-actin density and reported as fold differences from the WT levels (dotted line).

inhibited the GALNS activity by 40−50% at 10 μM concentration, which confirmed the modeling prediction of partial and weak binding of these compounds to the active cavity of GALNS. Similarly, Δ-unsaturated 2-sulfouronic acidN-sulfoglucosamine competed with the substrate of the human IDS, leading to a reduction of approximately 40% in enzyme activity.29 The pharmacological chaperones of the lysosomal enzyme aspartylglucosaminidase weakly inhibited the enzyme activity.49 Ezetimibe and pranlukast increased the GALNS thermal stability, indicating that they bind directly to this enzyme. These results agreed with those reported for Δ-unsaturated 2sulfouronic acid-N-sulfoglucosamine, which significantly increased the thermal stability of IDS.29 Similarly, glycomimetic ligands for human glucocerebrosidase increased its thermal stability between 5.6 and 21.7 °C, depending on the ligands and the inhibition mechanism (competitive, semi-irreversible, or irreversible).50

placebo.46,47 Recently, it was reported an agonist activity of pranlukast over the farnesoid X receptor (FXR).48 This could represent a potential drawback of pranlukast use as a pharmacological chaperone because activation of FXR may have an important adverse effect in the metabolic cholesterol elimination by repressing cholesterol 7α-hydroxylase (CYP7A1). Nevertheless, pranlukast was characterized as a moderately potent partial agonist of FXR with an EC50 of 15 μM,48 which is 15 000-fold higher than the concentration that showed the best pharmacological chaperone effects in this study. In this sense, we do not expect any additional adverse effect for pranlukast to those previously reported. Medicinal chemistry optimization of pranlukast may provide better analogues with more less off-target liabilities. Most pharmacological chaperones bind to the catalytic site of an enzyme and are reversible inhibitors that dissociate with the enzymes because of the high substrate concentrations in the lysosomal compartment.28 Ezetimibe and pranlukast 6182



Article

Figure 9. Effects of combination treatment of hrGALNS with ezetimibe or pranlukast on the reduction of lysosome size in MPS IVA patient fibroblasts. Coadministration of hrGALNS produced in the yeast P. pastoris and the pharmacological chaperones ezetimibe and pranlukast decreased the size of the lysosomes to WT levels. Cells were treated for 72 h with hrGALNS in the presence or absence of ezetimibe or pranlukast. The cells were stained with the LysoTracker Red DND-99 dye, and the images (9 images/well) were acquired using the IN Cell Analyzer 2200 imaging system. Results are presented as cell intensity normalized to the wild-type fluorescence level (dotted lines). All assays were performed in triplicate (ANOVA Sidak t-test **p < 0.01, ***p < 0.001, ****p < 0.0001). Scale bar: 100 μm.

hrGALNS might help to reduce immunogenicity, as the amount of protein used in ERT can be reduced.52 Prior to the treatment with the pharmacological chaperones, we identified the mutations present in the MPS IVA fibroblasts. The MPS IVA patient fibroblasts used in this study have the mutations p.R61W, p.R94C, p.F285del, p.A393S, and p.W405_T406del in the GALNS protein. The mutations p.R386C and in-frame deletions p.F285del and p.W405_T406del are associated with rapid disease progression and a severe growth reduction phenotype,53−55 while mutations p.R61W and p.R94C are associated with a mild/ attenuated phenotype.16,55 On the other hand, mutation p.A393S was predicted to be benign or neutral by PolyPhen2 and PROVEAN, respectively, and no reports for this mutation have been found in the literature. Another bioinformatics analysis showed that p.A393S induces structural changes in GALNS. All of these mutations can lead to a significant reduction in GALNS activity and protein level, resulting in autophagy disruption and an increase in lysosomal mass. In addition, because a mutated protein is synthetized,

Several factors affect the production of a recombinant protein, including the host, vectors, culture conditions, and protein activation and folding.51 Misfolded proteins can cause reduced activity and low production yields.34,35 Previously, we showed that the activity of hrGALNS expressed in E. coli was increased by improving protein folding through the control of gene expression, induction of osmoprotectants, and improvement in the formation of disulfide bonds.36 In addition, it has been reported that protein translocation is a bottleneck in the production of properly folded proteins and that several methods could be used to improve this process.34 We observed that ezetimibe and pranlukast increased the activity of hrGALNS produced in bacteria, yeast, and mammalian cells. However, when a combination of ezetimibe and pranlukast was used during the production of recombinant GALNS in HEK293 cells, it significantly decreased the GALNS activity. This decrease might be a consequence of an additive effect of enzyme inhibition by the two molecules. Nevertheless, the results have shown potential applications for the smallmolecule chaperone compounds to improve the production yield and activity of hrGALNS. The increase in activity of 6183



Article

subsequent increase of TFEB nuclear translocation.68 In primary hepatocytes, ezetimibe increased LC3B-II levels; the number of both autolysosomes and autophagic vacuoles; and the expression of autophagy-related genes such as Tfeb, Atg7, Lc3b, Atg3, Atg5, Atg12, Lc3a, Ulk1, Benc1, Sqstm1 (p62), and Lamp1.68 Similarly, in vivo administration of ezetimibe induced autophagy in the liver, as well as reduced the number of lipid droplets, hepatic triglycerides, and cholesterol levels in methionine- and choline-deficient diet-fed mice compared with controls.68 Therefore, the effect of ezetimibe on MPS IVA patient fibroblasts could be the result of both pharmacological chaperone activity and normalization of defective autophagy. Our results indicated that the efficacy of ERT for MPS IVA patients may be overcome by a combination therapy of hrGALNS with ezetimibe or pranlukast because the pharmacological chaperones can increase the activity of hrGALNS, reducing the dose needed for ERT. In addition, the effect of ezetimibe on autophagy can be functionally additive to ERT and may further improve the ERT’s therapeutic efficacy in MPS IVA patients. Our results are consistent with a previous report that showed that a coadministration of recombinant human acid α-glucosidase (rhGAA) with the pharmacological chaperone duvoglustat increased the half-life and plasma levels of rhGAA, resulting in a higher reduction of glycogen accumulation in heart and skeletal muscles compared to rhGAA used alone in the Pompe disease model.69 Recently, a clinical evaluation of this therapeutic option revealed a significant increase in rhGAA activity and protein levels in plasma and muscle, demonstrating the benefit of combinational therapy of ERT with a pharmacological chaperone compound.70 In this sense, Tomatsu et al.71 showed that an increase in the ERT halflife, by using an engineered rhGALNS carrying a bonetargeting peptide, significantly improved the biodistribution to bone and heart, as well as the therapeutic efficacy. Taken together, we consider that the limited effects in correcting the skeletal and cardiac abnormalities of the current MPS IVA ERT could be improved by increasing the half-life and activity of rhGALNS by combination therapy with a pharmacological chaperone.

they could be susceptible to be treated by pharmacological chaperones. Our results demonstrated that ezetimibe increased the GALNS activity levels by 1.2- to 2.5-fold and reduced lysosomal mass in all of the MPS IVA patient cells we examined. Pranlukast only increased the GALNS activity in patient cells with p.A393S or p.R61W/p.W405_T406del mutations without an obvious reduction in lysosomal mass. Recently, we showed that treatment of MPS IVA fibroblasts with a rhGALNS produced in P. pastoris reduced KS levels,33 suggesting that this GAG is stored in MPS IVA fibroblasts and that the reduction in lysosomal mass observed after treatment with the pharmacological chaperones could be associated with a KS reduction. It has been reported that the effects of pharmacological chaperones may depend on the particular mutations of the enzyme and properties of the compound. For instance, treatment of MPS II fibroblasts with Δ-unsaturated 2sulfouronic acid-N-sulfoglucosamine showed a 1.6- to 39.6-fold increase in IDS activity without a significant reduction of GAG level. 29 Similarly, treatment of MPS IVB and GM1gangliosidosis fibroblasts with the pharmacological chaperone (5aR)-5a-C-pentyl-4-epi-isofagomine increased the β-galactosidase activity by 1.5- to 35-fold.30 Treatment of Gaucher patient fibroblasts with different pharmacological chaperones resulted in up to a 2.5-fold increase in β-glucocerebrosidase activity and a significant reduction in the stored substrate.56,57 Finally, pharmacological chaperones led to a 2- to 4-fold increase in aspartylglucosaminidase activity in fibroblasts derived from patients with aspartylglucosaminuria, as well as improvement of protein processing and reduction of lysosomal mass.49 These previously reported findings suggest that a similar strategy could be employed to treat MPS IVA patients. However, it is important to evaluate the biodistribution of these drugs to the main affected tissues in MPS IVA patients, such as bone, heart, and cornea. Nevertheless, because circulation times increase the probability for a drug to reach the target disease sites,58 it could be expected that ezetimibe and pranlukast reach those tissues because of (1) longer halflife times (22 and 9 h, respectively)47,59 than MPS IVA ERT (35 min)60 and (2) higher administration frequency (daily or every other day) than ERT (once a week). In case that these drugs do not shown an acceptable biodistribution profile, there are some targeting alternatives that could be implemented,61,62 in addition to the possibility of drug properties optimization through medicinal chemistry. Autophagy malfunction has been widely reported in LSDs. For instance, inhibition or blockade of autophagic flux has been reported for neural ceroid lipofuscinoses, Gaucher disease, Niemann−Pick type C1 (NPC1), Pompe disease, and Danon disease, among others.63 However, other studies showed activation of the autophagy pathway, as observed in NPC164 or mucolipidosis type IV. 65 In the case of mucopolysaccharidoses, MPS I and MPS VII mice showed an increase in protein degradation, which was associated with an increase in autophagic flux.66 On the other hand, LC3 levels were decreased in MPS IIIC mice with increased autophagy activity.67 We found that both p62 and LC3B-II levels were reduced in the MSP IVA cells compared to the WT control. Treatment of MPS IVA fibroblasts with ezetimibe or pranlukast significantly increased the levels of p62 and LC3B-II, with higher p62 levels observed after the ezetimibe treatment. Recently, it was described that ezetimibe increases the autophagy flux in mice through AMPK activation and

4. CONCLUSIONS In this study, we have identified and characterized ezetimibe and pranlukast as the first pharmacological chaperones described for the lysosomal enzyme GALNS. Both compounds significantly increased the amounts and activities of hrGALNS produced in E. coli, P. pastoris, and HEK293 cells, indicating that both ezetimibe and pranlukast may be used to increase the production yields of hrGALNS. Ezetimibe significantly increased the protein level and activity of mutated GALNS in MPS IVA fibroblasts as well as significantly reduced lysosomal mass and ameliorated abnormal autophagy. The combination therapy of hrGALNS with ezetimibe or pranlukast additively reduced lysosomal mass in patientderived fibroblasts. Therefore, ezetimibe has potential for use as a monotherapy for MPS IVA patients. The combination therapy of ezetimibe or pranlukast with the reduced dose of ERT may provide a new therapeutic strategy to improve the efficacy of ERT for MPS IVA patients. 5. EXPERIMENTAL SECTION 5.1. Virtual Docking. Virtual docking was carried out using a previously reported three-dimensional GALNS structure20 and 6184



Article

AutoDock Vina72 against 11 421 compounds, called the ZINC In Man, a special subset of ZINC.73 Docking for each ligand was run 20 times and constrained to the active cavity (specifically, the grid box was centered between FGly 79 and the calcium ion). Results of the protein−ligand interactions are reported as the affinity energy (kcal mol−1).72 KS (1KES) and C6S (CID 24766) structures were retrieved from the RCSB-Protein Data Bank and PubChem, respectively. The structure of the artificial ligand 4MUGPS used in the GALNS activity assay74 was built using MarvinSketch at Marvin Suite (ChemAxon Ltd., Budapest, Hungary). Molecular dynamics analysis was done using GROMAC 4.5.5.75 Topology of ligands was generated using the Automated Topology Builder (ATB) and Repository version 2.2.76 Simulations were carried out for 20 ns. The trajectories were analyzed by rmsd (g_rms_d) and the affinity energy (g_lie_d). All simulations were done at the High-Performance Computing Center (ZINE) of Pontificia Universidad Javeriana (Bogotá, Colombia). 5.2. Production of Human Recombinant GALNS (hrGALNS). Production of hrGALNS in E. coli BL21(DE3) and P. pastoris GS115 was carried out a shaken-flask scale (100 mL) as previously reported.32,36,37,77 The production of hrGALNS in mammalian cells was performed using the HEK293 cells (ATCC CRL1573) transfected with the pCXN-GALNS vector (kindly donated by Tomatsu).39 The HEK293 cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM, Gibco, Thermo Fisher Scientific, Grand Island, NY, USA) supplemented with 15% fetal bovine serum (Eurobio, Les Ulis, France), penicillin 100 U mL−1, and streptomycin 100 U mL−1 (Walkersville, MD, USA) at 37 °C in a 5% CO2 incubator. Lipofectamine 2000 was used in the transfection as per the manufacturer’s instructions (Invitrogen, Thermo Fisher Scientific, San Jose, CA, USA). Ezetimibe and pranlukast (Sigma-Aldrich, St. Louis, MO, USA) were dissolved in DMSO and added at different concentrations during hrGALNS production. The GALNS activity was measured in the cell lysate (HEK293 cells) or cell supernatant (E. coli and P. pastoris). Recombinant GALNS produced in P. pastoris was purified from the culture medium following a previously reported protocol.32 Briefly, the culture medium (∼1.7 L) was filtered sequentially through 0.45 and 0.22 μm using polyether sulfone membranes (Pall Corp, Port Washington, NY, USA). Permeate was ultrafiltered through a 30 kDa cutoff membrane (Millipore, Billerica, MA, USA). The retentate was dialyzed in acetate buffer (25 mM, pH 5.0). Finally, hrGALNS was purified by a two-step process using a cation exchange chromatography, followed by size exclusion chromatography. Fractions with the highest GALNS activity were pooled, diafiltrated against 25 mM sodium acetate pH 5.0, and lyophilized. 5.3. Culture of Fibroblasts. WT and MPS IVA patient-derived skin fibroblasts were obtained from the Coriell Institute (Table 1). Cells were cultured in DMEM (Gibco, Thermo Fisher Scientific, Grand Island, NY, USA) supplemented with 10% fetal bovine serum (Eurobio, Les Ulis, France) at 37 °C in a CO2 incubator. Characterizations of mutations in the GALNS gene were performed by ACGT, Inc. (Wheeling, IL, USA) through exon sequencing. Gene variants were analyzed by using the Variant Annotation Integrator tool from the University of California Santa Cruz Genome Browser78 and further studied by PolyPhen279 and SIFT/PROVEAN.80 The point mutations (R386C, A393S, R61W, and R94C) were modeled by site-directed mutagenesis using the reported crystal structure of human GALNS (PDB 4FDI)14 on PyMOL v2.0.7 (Molecular Graphics System, v2.0 Schrödinger LLC), followed by an energetic minimization using Chimera v1.12.81 Deletions (F285del and W405_T406del) were modeled using the I-TASSER online server.82 FGly 79 was manually included within these models using PyMOL; a calcium ion was added between Asp39, Asp40, Asp288, and Asp28914,20 using YASARA View v18.4.24,83 followed by an energetic minimization using Chimera v1.12.81 The comparison of the models against the WT protein crystal was done using PyMOL, which compared the rmsd of the protein backbone to all the other atoms in the protein. Molecular docking of the modeled GALNS structures and the natural and artificial ligands was done using AutoDock Vina.72 The search space was centered between FGly79 and the calcium ion,

as previously described.20 Docking for each ligand was run 20 times and constrained to the active cavity. Protein−peptide interactions were reported as affinity energy (kcal mol−1)72 and were evaluated by using YASARA View v18.4.2483 and UCSF Chimera v1.12.81 5.4. LysoTracker Staining and Immunofluorescence Staining. HEK293 cells overexpressing GALNS were treated with the chaperone compounds for 48 h, followed by a cell wash and incubation with 50 nM LysoTracker Green DND-26 (Molecular Probes, Thermo Fisher Scientific, San Jose, CA, USA) in complete DMEM at 37 °C for 1 h. For the immunofluorescence staining, cells (after the compound treatment) were washed twice with 1X PBS, fixed with 4% paraformaldehyde, and permeabilized with 0.1% Triton X-100, followed by blocking with 2% bovine serum albumin in 1× TBS. After blocking, the cells were incubated overnight at 4 °C with a rabbit polyclonal anti-GALNS antibody (ab187516, Abcam) in the blocking buffer. Goat anti-rabbit IgG (H + L) cross-adsorbed, Alexa Fluor 633 antibody (A-21070, Thermo Fisher Scientific, San Jose, CA, USA) was added at a 1:1000 dilution in the blocking buffer. The cellular nuclei were stained with 4′,6-diamidino-2-phenylindole dihydrochloride (DAPI, Thermo Fisher Scientific, San Jose, CA, USA). The cells were visualized using an Axio Observer Z1 microscope (ZEISS, Birkerød, Denmark) with a Filter set 109 HE LED (E), containing beam splitter TBS 405 + 493 + 575 and emission filter TBP 425/29 + 514/31 + 632/100; this configuration collected DAPI, LysoTracker Green and anti-GANLS signals, respectively. Images were processed by using NIH ImageJ software.84 To evaluate the effects of ezetimibe and pranlukast on the reduction of lysosomal mass in 96-well plates, cells were seeded in black clear bottomed plates (Greiner Bio-One, #655090, Monroe, NC, USA) at 4000 cells/well and cultured overnight. On the day of the experiment, MPS IVA and WT fibroblasts were treated with different concentrations of ezetimibe or pranlukast in DMEM for 24 h. The cells were then stained with a 50 nM LysoTracker Red DND99 dye in the medium at 37 °C for 1 h, followed by two plate washes with DPBS. The plates were fixed and stained simultaneously in 3.2% paraformaldehyde solution with the Hoechst dye at a 1:5000 dilution for 30 min at room temperature. The plates were washed twice using DPBS and stored with 100 μL/well DPBS at 4 °C until imaging. The images (9 images/well) were acquired using the INCell Analyzer 2200 imaging system (GE Healthcare Bio-Sciences, Pittsburgh, PA, USA). INCell image analysis software (GE Healthcare Bio-Sciences) was used to quantify the fluorescence intensity (LysoTracker staining). The fluorescence intensity corresponds to the average of all the pixels in a cell and averaged across all the cells within an image. The DAPI (excitation = 350 ± 50 nm, emission = 455 ± 50 nm) and Texas Red (excitation = 545 ± 20 nm, emission = 593 ± 20 nm) filter sets were used to visualize Hoechst nuclear staining and LysoTracker Red DND-99 staining, respectively. 5.5. Thermal Shift Assay. Thermal stability was carried out by the thermal shift assay.85 For this purpose, 5 μM hrGALNS, in 25 mM sodium acetate pH 5.0, was mixed with 1 μM ezetimibe or pranlukast and 20× SYPRO orange (Molecular Probes, Thermo Fisher Scientific, Eugene, OR, USA). Thermal denaturation was carried out in an Applied Biosystems ViiA7 with ViiA7 RUO software (Applied Biosystems, Thermo Fisher Scientific, Carlsbad, CA, USA). Melting curve was set as follows: (1) 2:00 held at 25 °C, (2) ramped up in 1 °C/30 s increments to a final temperature of 95 °C, and (3) 2:00 held at 95 °C. The Tm was calculated by plotting the first derivative of the fluorescence emission as a function of temperature (−dF/dT). All assays were performed in triplicate. 5.6. GALNS Activity. The GALNS activity was assayed by using 4-methylumbelliferyl-β- D -galactopyranoside-6-sulfate (Toronto Chemicals Research, North York, ON, Canada) as a substrate.74,86 One unit (U) was defined as the amount of enzyme catalyzing 1 nmol substrate per hour. Specific GALNS activity was expressed as U/mg of protein as determined by the Lowry assay. To evaluate the inhibitory effect of ezetimibe or pranlukast, hrGALNS was coincubated with the substrate and various concentrations of compounds, followed by the detection of fluorescent product generation. To evaluate the effect of ezetimibe or pranlukast on GALNS activity in cells, 1 × 105 cells/well 6185



Article

were seeded in a six-well plate and cultured for 1 day. The compound dilutions were added to the cells and incubated for 48 h, followed by cell lysis using 1% sodium deoxycholate (Sigma-Aldrich). The enzyme activities of cell lysates were determined as described above. MPS IVA and WT fibroblasts treated with DMSO were used as controls. All experiments were performed in triplicate. 5.7. Western Blot. Western blot analysis against GALNS, p62, and LC3B was performed on ezetimibe- or pranlukast-treated MPS IVA and WT fibroblasts using DMSO as a control. Cells were seeded in six-well plates as described above. Equivalent amounts of cell lysates (20 μg) were loaded and run on NuPAGE 10% Bis−Tris Protein Gels (Invitrogen, Thermo Fisher Scientific) and transferred to polyvinylidene difluoride membranes using iBlot Transfer Stack and iBlot 2 Dry Blotting System (Invitrogen, Thermo Fisher Scientific). Membranes were blocked with StartingBlock (Invitrogen, Thermo Fisher Scientific) at room temperature for 1 h. After blocking, the membranes were incubated overnight at 4 °C with the primary antibodies including the mouse monoclonal anti-P62 (SQSTM1(D3)) antibody in the blocking buffer (SC-28359, Santa Cruz Biotechnology), rabbit monoclonal anti-LC3B antibody (#3668S, Cell Signaling Technology), rabbit polyclonal anti-GALNS antibody (ab187516, Abcam), or mouse monoclonal anti-β-actin antibody (#3700S, Cell Signaling Technology). The membranes were then washed and incubated with a secondary antibody of goat anti-mouse IgG (#7076S) or goat anti-rabbit IgG (#7074P2, Cell Signaling Technology, Danvers, MA, USA) conjugated with horseradish peroxidase (HRP, 1:3000 dilution in blocking buffer). The specific protein bands were visualized using a chemiluminescence reagent (Luminata Western HRP Chemiluminescence Substrate, EMD Millipore, Burlington, MA, USA) and were subsequently analyzed by using NIH ImageJ software.84 5.8. Statistical Analysis. The results are shown as the mean ± the standard deviation (SD) and were analyzed by an analysis of variance (ANOVA), followed by the Sidak t-test when appropriate. Differences between groups were considered significant when p < 0.05 on GraphPad PRISM 7.0.

■

enzymes. C.J.A.-.D, K.G., R.L., and W.Z. conceived and designed the experiments. C.J.A.-D., K.G., and W.Z. wrote the paper. All authors read and approved the final manuscript. Notes

The authors declare no competing financial interest.

■

ACKNOWLEDGMENTS C.J.A.-D. was supported by Pontificia Universidad Javeriana [grant ID 7204 and 7520] and COLCIENCIAS [grant ID 5174contract no. 120356933205 and grant ID 5170 contract no. 120356933427]. A.R.-L. received a doctoral scholarship from Pontificia Universidad Javeriana. C.J.A.-D. received a scholarship from Fulbright Colombia. K.G., R.L., and W.Z. were supported by the Intramural Research Program of the National Center for Advancing Translational Sciences, National Institutes of Health, USA. Icons on the Table of Contents Graphic were obtained from Smartline and Pixel Perfect from www.flaticon.com. The authors declare that they have no competing interests. The authors thank Dr. DeeAnn Visk, a medical writer and editor, for editing the manuscript.

■

ABBREVIATIONS MPS IVA, mucopolysaccharidosis type IV A; ERT, enzyme replacement therapy; GALNS, N-acetylgalactosamine-6-sulfate sulfatase; hrGALNS, human recombinant GALNS; LSD, lysosomal storage disease; GAGs, glycosaminoglycans; KS, keratan sulfate; C6S, chondroitin-6-sulfate; HSCT, hematopoietic stem cell transplantation; 4MUGPS, 4-methylumbelliferyl-β-D-galactopyranoside-6-sulfate; hrGALNS, human recombinant GALNS; WT, wild-type; IDS, iduronate-2sulfatase; NPC1, Niemann−Pick type C1; rhGAA., recombinant human acid α-glucosidase

■

ASSOCIATED CONTENT

* Supporting Information S

(1) Sawamoto, K.; Alméciga-Díaz, C. J.; Mason, R. W.; Orii, T.; Tomatsu, S. Mucopolysaccharidosis Type IVA: Clinical Features, Biochemistry, Diagnosis, Genetics, and Treatment. In Mucopolysaccharidoses Update (2 Volume Set); Tomatsu, S., Lavery, C., Giugliani, R., Harmatz, P., Scarpa, M., Węgrzyn, G., Orii, T., Eds.; Nova Science Publishers, Inc.: Hauppauge, NY, 2018; Vol. I, pp 235−272. (2) Leadley, R. M.; Lang, S.; Misso, K.; Bekkering, T.; Ross, J.; Akiyama, T.; Fietz, M.; Giugliani, R.; Hendriksz, C. J.; Hock, N. L.; McGill, J.; Olaye, A.; Jain, M.; Kleijnen, J. A systematic review of the prevalence of Morquio A syndrome: challenges for study reporting in rare diseases. Orphanet J. Rare Dis. 2014, 9, 173−190. (3) Khan, S.; Alméciga-Díaz, C. J.; Sawamoto, K.; Mackenzie, W. G.; Theroux, M. C.; Pizarro, C.; Mason, R. W.; Orii, T.; Tomatsu, S. Mucopolysaccharidosis IVA and glycosaminoglycans. Mol. Genet. Metab. 2017, 120, 78−95. (4) Taylor, M.; Khan, S.; Stapleton, M.; Wang, J.; Chen, J.; Wynn, R.; Yabe, H.; Chinen, Y.; Boelens, J. J.; Mason, R. W.; Kubaski, F.; Horovitz, D. D. G.; Barth, A. L.; Serafini, M.; Bernardo, M. E.; Kobayashi, H.; Orii, K. E.; Suzuki, Y.; Orii, T.; Tomatsu, S. Hematopoietic stem cell transplantation for mucopolysaccharidoses: Past, present, and future. Biol. Blood Marrow Transplant. 2019, DOI: 10.1016/j.bbmt.2019.1002.1012. (5) Tomatsu, S.; Sawamoto, K.; Shimada, T.; Bober, M. B.; Kubaski, F.; Yasuda, E.; Mason, R. W.; Khan, S.; Alméciga-Díaz, C. J.; Barrera, L. A.; Mackenzie, W. G.; Orii, T. Enzyme replacement therapy for treating mucopolysaccharidosis type IVA (Morquio A syndrome): effect and limitations. Expert Opin. Orphan Drugs 2015, 3, 1279− 1290. (6) Hendriksz, C. J.; Burton, B.; Fleming, T. R.; Harmatz, P.; Hughes, D.; Jones, S. A.; Lin, S.-P.; Mengel, E.; Scarpa, M.; Valayannopoulos, V.; Giugliani, R.; Slasor, P.; Lounsbury, D.;

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.jmedchem.9b00428. Top 20 hits of the compounds interacting with hrGALNS after virtual screening against the ZINC In Man subset from ZINC; protein−ligand interactions between GALNS, KS, C6S, 4MUGPS, ezetimibe, and pranlukast; and production of hrGALNS in P. pastoris at the bioreactor scale (1.7 L) (PDF) PDB-formatted coordinates of GALNS docked with KS, C6S, 4MUGPS, ezetimibe, and pranlukast (ZIP) Molecular formula strings (CSV)

■

REFERENCES

AUTHOR INFORMATION

Corresponding Authors

*E-mail: [email protected]. Phone: +57-1 3208320 ext. 4140. Fax: +57-1 3208320 ext. 4099 (C.J.A.-D.). *E-mail: [email protected]. Phone: 1-301-827-5722 (W.Z.). ORCID

Carlos J. Alméciga-Diaz: 0000-0001-6484-1173 Author Contributions

C.J.A.-D., O.A.H., A.R.-L., E.G., and R.G. performed the experiments. C.J.A.-D., S.O.A., M.A.P.-T., and A.F.R.-R. performed the bioinformatics analysis and simulations. A.R.L., R.G., and L.N.P.-V. produced and purified recombinant 6186



Article

Dummer, W. Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo-controlled study. J. Inherited Metab. Dis. 2014, 37, 979−990. (7) Hendriksz, C. J.; Giugliani, R.; Harmatz, P.; Mengel, E.; Guffon, N.; Valayannopoulos, V.; Parini, R.; Hughes, D.; Pastores, G. M.; Lau, H. A.; Al-Sayed, M. D.; Raiman, J.; Yang, K.; Mealiffe, M.; Haller, C. Multi-domain impact of elosufase alfa in Morquio A syndrome in the pivotal phase III trial. Mol. Genet. Metab. 2015, 114, 178−185. (8) Doherty, C.; Stapleton, M.; Piechnik, M.; Mason, R. W.; Mackenzie, W. G.; Yamaguchi, S.; Kobayashi, H.; Suzuki, Y.; Tomatsu, S. Effect of enzyme replacement therapy on the growth of patients with Morquio A. J. Hum. Genet. 2019, 64, 625−635. (9) Schweighardt, B.; Tompkins, T.; Lau, K.; Jesaitis, L.; Qi, Y.; Musson, D. G.; Farmer, P.; Haller, C.; Shaywitz, A. J.; Yang, K.; O’Neill, C. A. Immunogenicity of elosulfase alfa, an enzyme replacement therapy in patients with Morquio A syndrome: results from MOR-004, a phase III trial. Clin. Ther. 2015, 37, 1012−1021. (10) Chinen, Y.; Higa, T.; Tomatsu, S.; Suzuki, Y.; Orii, T.; Hyakuna, N. Long-term therapeutic efficacy of allogenic bone marrow transplantation in a patient with mucopolysaccharidosis IVA. Mol. Genet. Metab. Rep. 2014, 1, 31−41. (11) Yabe, H.; Tanaka, A.; Chinen, Y.; Kato, S.; Sawamoto, K.; Yasuda, E.; Shintaku, H.; Suzuki, Y.; Orii, T.; Tomatsu, S. Hematopoietic stem cell transplantation for Morquio A syndrome. Mol. Genet. Metab. 2016, 117, 84−94. (12) Wang, J.; Luan, Z.; Jiang, H.; Fang, J.; Qin, M.; Lee, V.; Chen, J. Allogeneic hematopoietic stem cell transplantation in thirty-four pediatric cases of mucopolysaccharidosis-A ten-year report from the China children transplant group. Biol. Blood Marrow Transplant. 2016, 22, 2104−2108. (13) Masue, M.; Sukegawa, K.; Orii, T.; Hashimoto, T. Nacetylgalactosamine-6-sulfate sulfatase in human placenta: purification and characteristics. J. Biochem. 1991, 110, 965−970. (14) Rivera-Colón, Y.; Schutsky, E. K.; Kita, A. Z.; Garman, S. C. The structure of human GALNS reveals the molecular basis for mucopolysaccharidosis IV A. J. Mol. Biol. 2012, 423, 736−751. (15) Stenson, P. D.; Mort, M.; Ball, E. V.; Evans, K.; Hayden, M.; Heywood, S.; Hussain, M.; Phillips, A. D.; Cooper, D. N. The Human Gene Mutation Database: towards a comprehensive repository of inherited mutation data for medical research, genetic diagnosis and next-generation sequencing studies. Hum. Genet. 2017, 136, 665−677. (16) Tomatsu, S.; Montaño, A. M.; Nishioka, T.; Gutierrez, M. A.; Peña, O. M.; Tranda firescu, G. G.; Lopez, P.; Yamaguchi, S.; Noguchi, A.; Orii, T. Mutation and polymorphism spectrum of the GALNS gene in mucopolysaccharidosis IVA (Morquio A). Hum. Mutat. 2005, 26, 500−512. (17) Sukegawa, K.; Nakamura, H.; Kato, Z.; Tomatsu, S.; Montaño, A. M.; Fukao, T.; Toietta, G.; Tortora, P.; Orii, T.; Kondo, N. Biochemical and structural analysis of missense mutations in Nacetylgalactosamine-6-sulfate sulfatase causing mucopolysaccharidosis IVA phenotypes. Hum. Mol. Genet. 2000, 9, 1283−1290. (18) Montaño, A. M.; Sukegawa, K.; Kato, Z.; Carrozzo, R.; Di Natale, P.; Christensen, E.; Orii, K. O.; Orii, T.; Kondo, N.; Tomatsu, S. Effect of “attenuated” mutations in mucopolysaccharidosis IVA on molecular phenotypes of N-acetylgalactosamine-6-sulfate sulfatase. J. Inherited Metab. Dis. 2007, 30, 758−767. (19) Sudhakar, S. C.; Mahalingam, K. Structural and functional analysis of N-acetylgalactosamine-6-sulfate sulfatase using bioinformatics tools: Insight into mucopolysaccharidosis IVA. J. Pharma Res. 2011, 4, 3958−3962. (20) Olarte-Avellaneda, S.; Rodríguez-López, A.; Alméciga-Díaz, C. J.; Barrera, L. A. Computational analysis of human N-acetylgalactosamine-6-sulfate sulfatase enzyme: an update in genotype-phenotype correlation for Morquio A. Mol. Biol. Rep. 2014, 41, 7073−7088. (21) Leidenheimer, N. J. Pharmacological chaperones: Beyond conformational disorders. Targeting Trafficking in Drug Development; Handbook of Experimental Pharmacology; Springer, 2018; Vol. 245, pp 135−153.

(22) Tao, Y.-X.; Conn, P. M. Pharmacoperones as novel therapeutics for diverse protein conformational diseases. Physiol. Rev. 2018, 98, 697−725. (23) Parenti, G.; Moracci, M.; Fecarotta, S.; Andria, G. Pharmacological chaperone therapy for lysosomal storage diseases. Future Med. Chem. 2014, 6, 1031−1045. (24) Valenzano, K. J.; Khanna, R.; Powe, A. C.; Boyd, R.; Lee, G.; Flanagan, J. J.; Benjamin, E. R. Identification and characterization of pharmacological chaperones to correct enzyme deficiencies in lysosomal storage disorders. Assay Drug Dev. Technol. 2011, 9, 213−235. (25) Pereira, D. M.; Valentão, P.; Andrade, P. B. Tuning protein folding in lysosomal storage diseases: the chemistry behind pharmacological chaperones. Chem. Sci. 2018, 9, 1740−1752. (26) Hughes, D. A.; Nicholls, K.; Shankar, S. P.; Sunder-Plassmann, G.; Koeller, D.; Nedd, K.; Vockley, G.; Hamazaki, T.; Lachmann, R.; Ohashi, T.; Olivotto, I.; Sakai, N.; Deegan, P.; Dimmock, D.; Eyskens, F.; Germain, D. P.; Goker-Alpan, O.; Hachulla, E.; Jovanovic, A.; Lourenco, C. M.; Narita, I.; Thomas, M.; Wilcox, W. R.; Bichet, D. G.; Schiffmann, R.; Ludington, E.; Viereck, C.; Kirk, J.; Yu, J.; Johnson, F.; Boudes, P.; Benjamin, E. R.; Lockhart, D. J.; Barlow, C.; Skuban, N.; Castelli, J. P.; Barth, J.; Feldt-Rasmussen, U. Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study. J. Med. Genet. 2017, 54, 288−296. (27) Parenti, G.; Andria, G.; Valenzano, K. J. Pharmacological chaperone therapy: preclinical development, clinical translation, and prospects for the treatment of lysosomal storage disorders. Mol. Ther. 2015, 23, 1138−1148. (28) Boyd, R. E.; Lee, G.; Rybczynski, P.; Benjamin, E. R.; Khanna, R.; Wustman, B. A.; Valenzano, K. J. Pharmacological chaperones as therapeutics for lysosomal storage diseases. J. Med. Chem. 2013, 56, 2705−2725. (29) Hoshina, H.; Shimada, Y.; Higuchi, T.; Kobayashi, H.; Ida, H.; Ohashi, T. Chaperone effect of sulfated disaccharide from heparin on mutant iduronate-2-sulfatase in mucopolysaccharidosis type II. Mol. Genet. Metab. 2018, 123, 118−122. (30) Front, S.; Biela-Banaś, A.; Burda, P.; Ballhausen, D.; Higaki, K.; Caciotti, A.; Morrone, A.; Charollais-Thoenig, J.; Gallienne, E.; Demotz, S.; Martin, O. R. (5aR)-5a-C-Pentyl-4-epi-isofagomine: A powerful inhibitor of lysosomal beta-galactosidase and a remarkable chaperone for mutations associated with GM1-gangliosidosis and Morquio disease type B. Eur. J. Med. Chem. 2017, 126, 160−170. (31) Olarte-Avellaneda, S.; Rodríguez-López, A.; Alméciga-Díaz, C. In-silico Analysis of the Active Cavity of N-acetylgalactosamine-6sulfate Sulfatase in Eight Species. In Advances in Computational Biology; Castillo, L. F., Cristancho, M., Isaza, G., Pinzón, A., Corchado, J. M., Eds.; Springer International Publishing, 2014; pp 141−146. (32) Rodríguez-López, A.; Alméciga-Díaz, C. J.; Sánchez, J.; Moreno, J.; Beltran, L.; Díaz, D.; Pardo, A.; Ramírez, A. M.; Espejo-Mojica, A. J.; Pimentel, L.; Barrera, L. A. Recombinant human N-acetylgalactosamine-6-sulfate sulfatase (GALNS) produced in the methylotrophic yeast Pichia pastoris. Sci. Rep. 2016, 6, 29329−29342. (33) Rodriguez-López, A.; Pimentel-Vera, L. N.; Espejo-Mojica, A. J.; Van, H. A.; Tiels, P.; Tomatsu, S.; Callewaert, N.; Almeciga-Diaz, C. J. Characterization of human recombinant N-acetylgalactosamine6-sulfate sulfatase produced in Pichia pastoris as potential enzyme for mucopolysaccharidosis IVA treatment. J. Pharm. Sci. 2019, DOI: 10.1016/j.xphs.2019.03.034. (34) Delic, M.; Gö ngrich, R.; Mattanovich, D.; Gasser, B. Engineering of protein folding and secretion-strategies to overcome bottlenecks for efficient production of recombinant proteins. Antioxid. Redox Signaling 2014, 21, 414−437. (35) Gasser, B.; Prielhofer, R.; Marx, H.; Maurer, M.; Nocon, J.; Steiger, M.; Puxbaum, V.; Sauer, M.; Mattanovich, D. Pichia pastoris: protein production host and model organism for biomedical research. Future Microbiol. 2013, 8, 191−208. 6187



Article

(36) Reyes, L. H.; Cardona, C.; Pimentel, L.; Rodriguez-Lopez, A.; Almeciga-Diaz, C. J. Improvement in the production of the human recombinant enzyme N-acetylgalactosamine-6-sulfatase (rhGALNS) in Escherichia coli using synthetic biology approaches. Sci. Rep. 2017, 7, 5844−5858. (37) Mosquera, A.; Rodríguez, A.; Soto, C.; Leonardi, F.; Espejo, A.; Sánchez, O. F.; Alméciga-Díaz, C. J.; Barrera, L. A. Characterization of a recombinant N-acetylgalactosamine-6-sulfate sulfatase produced in E. coli for enzyme replacement therapy of Morquio A disease. Process Biochem. 2012, 47, 2097−2102. (38) Hernandez, A.; Velasquez, O.; Leonardi, F.; Soto, C.; Rodriguez, A.; Lizaraso, L.; Mosquera, A.; Bohorquez, J.; Coronado, A.; Espejo, A.; Sierra, R.; Sanchez, O. F.; Almeciga-Diaz, C. J.; Barrera, L. A. Effect of culture conditions and signal peptide on production of human recombinant N-acetylgalactosamine-6-sulfate sulfatase in Escherichia coli BL21. J. Microbiol. Biotechnol. 2013, 23, 689−698. (39) Tomatsu, S.; Montaño, A. M.; Gutierrez, M.; Grubb, J. H.; Oikawa, H.; Dung, V. C.; Ohashi, A.; Nishioka, T.; Yamada, M.; Yamada, M.; Tosaka, Y.; Trandafirescu, G. G.; Orii, T. Characterization and pharmacokinetic study of recombinant human Nacetylgalactosamine-6-sulfate sulfatase. Mol. Genet. Metab. 2007, 91, 69−78. (40) Xu, M.; Liu, K.; Swaroop, M.; Sun, W.; Dehdashti, S. J.; McKew, J. C.; Zheng, W. A phenotypic compound screening assay for lysosomal storage diseases. J. Biomol. Screening 2014, 19, 168−175. (41) Lloyd-Evans, E.; Morgan, A. J.; He, X.; Smith, D. A.; ElliotSmith, E.; Sillence, D. J.; Churchill, G. C.; Schuchman, E. H.; Galione, A.; Platt, F. M. Niemann-Pick disease type C1 is a sphingosine storage disease that causes deregulation of lysosomal calcium. Nat. Med. 2008, 14, 1247−1255. (42) Marugan, J. J.; Huang, W.; Motabar, O.; Zheng, W.; Xiao, J.; Patnaik, S.; Southall, N.; Westbroek, W.; Lea, W. A.; Simeonov, A.; Goldin, E.; Debernardi, M. A.; Sidransky, E. Non-iminosugar glucocerebrosidase small molecule chaperones. Med. Chem. Commun. 2012, 3, 56−60. (43) Zheng, W.; Padia, J.; Urban, D. J.; Jadhav, A.; Goker-Alpan, O.; Simeonov, A.; Goldin, E.; Auld, D.; LaMarca, M. E.; Inglese, J.; Austin, C. P.; Sidransky, E. Three classes of glucocerebrosidase inhibitors identified by quantitative high-throughput screening are chaperone leads for Gaucher disease. Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 13192−13197. (44) Berardi, A. S.; Pannuzzo, G.; Graziano, A.; CostantinoCeccarini, E.; Piomboni, P.; Luddi, A. Pharmacological chaperones increase residual beta-galactocerebrosidase activity in fibroblasts from Krabbe patients. Mol. Genet. Metab. 2014, 112, 294−301. (45) Yilmazer, B.; Yagci, Z. B.; Bakar, E.; Ozden, B.; Ulgen, K.; Ozkirimli, E. Investigation of novel pharmacological chaperones for Gaucher disease. J. Mol. Graphics Modell. 2017, 76, 364−378. (46) Phan, B. A.; Dayspring, T. D.; Toth, P. P. Ezetimibe therapy: mechanism of action and clinical update. Vasc. Health Risk Manag. 2012, 8, 415−427. (47) Keam, S. J.; Lyseng-Williamson, K. A.; Goa, K. L. Pranlukast: a review of its use in the management of asthma. Drugs 2003, 63, 991− 1019. (48) Schierle, S.; Schmidt, J.; Kaiser, A.; Merk, D. Selective optimization of pranlukast to farnesoid X receptor modulators. ChemMedChem 2018, 13, 2530−2545. (49) Banning, A.; Gulec, C.; Rouvinen, J.; Gray, S. J.; Tikkanen, R. Identification of small molecule compounds for pharmacological chaperone therapy of aspartylglucosaminuria. Sci. Rep. 2016, 6, 37583−37595. (50) Bdira, F. B.; Kallemeijn, W.; Oussoren, S.; Scheij, S.; Bleijlevens, B.; Florea, B.; van Roomen, C.; Ottenhoff, R.; van Kooten, M.; Walvoort, M.; Witte, M.; Boot, R.; Ubbink, M.; Overkleeft, H.; Aerts, J. Stabilization of glucocerebrosidase by active site occupancy. ACS Chem. Biol. 2017, 12, 1830−1841. (51) Demain, A. L.; Vaishnav, P. Production of recombinant proteins by microbes and higher organisms. Biotechnol. Adv. 2009, 27, 297−306.

(52) Maas, C.; Hermeling, S.; Bouma, B.; Jiskoot, W.; Gebbink, M. F. B. G. A role for protein misfolding in immunogenicity of biopharmaceuticals. J. Biol. Chem. 2007, 282, 2229−2236. (53) Tomatsu, S.; Dieter, T.; Schwartz, I. V.; Sarmient, P.; Giugliani, R.; Barrera, L. A.; Guelbert, N.; Kremer, R.; Repetto, G. M.; Gutierrez, M. A.; Nishioka, T.; Serrato, O. P.; Montaño, A. M.; Yamaguchi, S.; Noguchi, A. Identification of a common mutation in mucopolysaccharidosis IVA: correlation among genotype, phenotype, and keratan sulfate. J. Hum. Genet. 2004, 49, 490−494. (54) Morrone, A.; Tylee, K. L.; Al-Sayed, M.; Brusius-Facchin, A. C.; Caciotti, A.; Church, H. J.; Coll, M. J.; Davidson, K.; Fietz, M. J.; Gort, L.; Hegde, M.; Kubaski, F.; Lacerda, L.; Laranjeira, F.; LeistnerSegal, S.; Mooney, S.; Pajares, S.; Pollard, L.; Ribeiro, I.; Wang, R. Y.; Miller, N. Molecular testing of 163 patients with Morquio A (Mucopolysaccharidosis IVA) identifies 39 novel GALNS mutations. Mol. Genet. Metab. 2014, 112, 160−170. (55) Tomatsu, S.; Fukuda, S.; Cooper, A.; Wraith, J. E.; Ferreira, P.; Di Natale, P.; Tortora, P.; Fujimoto, A.; Kato, Z.; Yamada, N.; Isogai, K.; Yamagishi, A.; Sukegawa, K.; Suzuki, Y.; Shimozawa, N.; Kondo, N.; Sly, W. S.; Orii, T. Fourteen novel mucopolysaccharidosis IVA producing mutations in GALNS gene. Hum. Mutat. 1997, 10, 368− 375. (56) Castilla, J.; Rísquez, R.; Higaki, K.; Nanba, E.; Ohno, K.; Suzuki, Y.; Díaz, Y.; Ortiz Mellet, C.; García Fernández, J. M.; Castillón, S. Conformationally-locked N-glycosides: exploiting longrange non-glycone interactions in the design of pharmacological chaperones for Gaucher disease. Eur. J. Med. Chem. 2015, 90, 258− 266. (57) Laigre, E.; Hazelard, D.; Casas, J.; Serra-Vinardell, J.; Michelakakis, H.; Mavridou, I.; Aerts, J. M. F. G.; Delgado, A.; Compain, P. Investigation of original multivalent iminosugars as pharmacological chaperones for the treatment of Gaucher disease. Carbohydr. Res. 2016, 429, 98−104. (58) Gouveia, V. M.; Lima, S. C. A.; Nunes, C.; Reis, S. NonBiologic nanodelivery therapies for rheumatoid arthritis. J. Biomed. Nanotechnol. 2015, 11, 1701−1721. (59) Cicero, A. F. G.; Bove, M.; Borghi, C. Pharmacokinetics, pharmacodynamics and clinical efficacy of non-statin treatments for hypercholesterolemia. Expert Opin. Drug Metab. Toxicol. 2018, 14, 9− 15. (60) Qi, Y.; Musson, D. G.; Schweighardt, B.; Tompkins, T.; Jesaitis, L.; Shaywitz, A. J.; Yang, K.; O’Neill, C. A. Pharmacokinetic and pharmacodynamic evaluation of elosulfase alfa, an enzyme replacement therapy in patients with Morquio A syndrome. Clin. Pharmacokinet. 2014, 53, 1137−1147. (61) Stapleton, M.; Sawamoto, K.; Alméciga-Díaz, C.; Mackenzie, W.; Mason, R.; Orii, T.; Tomatsu, S. Development of bone targeting drugs. Int. J. Mol. Sci. 2017, 18, 1345−1360. (62) Madni, A.; Rahem, M. A.; Tahir, N.; Sarfraz, M.; Jabar, A.; Rehman, M.; Kashif, P. M.; Badshah, S. F.; Khan, K. U.; Santos, H. A. Non-invasive strategies for targeting the posterior segment of eye. Int. J. Pharm. 2017, 530, 326−345. (63) Seranova, E.; Connolly, K. J.; Zatyka, M.; Rosenstock, T. R.; Barrett, T.; Tuxworth, R. I.; Sarkar, S. Dysregulation of autophagy as a common mechanism in lysosomal storage diseases. Essays Biochem. 2017, 61, 733−749. (64) Pacheco, C. D.; Elrick, M. J.; Lieberman, A. P. Tau deletion exacerbates the phenotype of Niemann-Pick type C mice and implicates autophagy in pathogenesis. Hum. Mol. Genet. 2009, 18, 956−965. (65) Vergarajauregui, S.; Connelly, P. S.; Daniels, M. P.; Puertollano, R. Autophagic dysfunction in mucolipidosis type IV patients. Hum. Mol. Genet. 2008, 17, 2723−2737. (66) Woloszynek, J. C.; Kovacs, A.; Ohlemiller, K. K.; Roberts, M.; Sands, M. S. Metabolic adaptations to interrupted glycosaminoglycan recycling. J. Biol. Chem. 2009, 284, 29684−29691. (67) Pshezhetsky, A. V. Lysosomal storage of heparan sulfate causes mitochondrial defects, altered autophagy, and neuronal death in the 6188



Article

mouse model of mucopolysaccharidosis III type C. Autophagy 2016, 12, 1059−1060. (68) Kim, S. H.; Kim, G.; Han, D. H.; Lee, M.; Kim, I.; Kim, B.; Kim, K. H.; Song, Y.-M.; Yoo, J. E.; Wang, H. J.; Bae, S. H.; Lee, Y.H.; Lee, B.-W.; Kang, E. S.; Cha, B.-S.; Lee, M.-S. Ezetimibe ameliorates steatohepatitis via AMP activated protein kinase-TFEBmediated activation of autophagy and NLRP3 inflammasome inhibition. Autophagy 2017, 13, 1767−1781. (69) Khanna, R.; Flanagan, J. J.; Feng, J.; Soska, R.; Frascella, M.; Pellegrino, L. J.; Lun, Y.; Guillen, D.; Lockhart, D. J.; Valenzano, K. J. The pharmacological chaperone AT2220 increases recombinant human acid alpha-glucosidase uptake and glycogen reduction in a mouse model of Pompe disease. PLoS One 2012, 7, e40776−e40718. (70) Kishnani, P.; Tarnopolsky, M.; Roberts, M.; Sivakumar, K.; Dasouki, M.; Dimachkie, M. M.; Finanger, E.; Goker-Alpan, O.; Guter, K. A.; Mozaffar, T.; Pervaiz, M. A.; Laforet, P.; Levine, T.; Adera, M.; Lazauskas, R.; Sitaraman, S.; Khanna, R.; Benjamin, E.; Feng, J.; Flanagan, J. J.; Barth, J.; Barlow, C.; Lockhart, D. J.; Valenzano, K. J.; Boudes, P.; Johnson, F. K.; Byrne, B. Duvoglustat HCl increases systemic and tissue exposure of active acid alphaglucosidase in Pompe patients co-administered with alglucosidase alpha. Mol. Ther. 2017, 25, 1199−1208. (71) Tomatsu, S.; Montaño, A. M.; Dung, V. C.; Ohashi, A.; Oikawa, H.; Oguma, T.; Orii, T.; Barrera, L.; Sly, W. S. Enhacement of drug delivery: Enzyme-replacement therapy for murine Morquio A syndrome. Mol. Ther. 2010, 18, 1094−1102. (72) Trott, O.; Olson, A. J. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 2010, 31, 455− 461. (73) Irwin, J. J.; Sterling, T.; Mysinger, M. M.; Bolstad, E. S.; Coleman, R. G. ZINC: a free tool to discover chemistry for biology. J. Chem. Inf. Model. 2012, 52, 1757−1768. (74) van Diggelen, O. P.; Zhao, H.; Kleijer, W. J.; Janse, H. C.; Poorthuis, B. J. H. M.; van Pelt, J.; Kamerling, J. P.; Galjaard, H. A fluorimetric enzyme assay for the diagnosis of Morquio disease type A (MPS IV A). Clin. Chim. Acta 1990, 187, 131−139. (75) Pronk, S.; Páll, S.; Schulz, R.; Larsson, P.; Bjelkmar, P.; Apostolov, R.; Shirts, M. R.; Smith, J. C.; Kasson, P. M.; van der Spoel, D.; Hess, B.; Lindahl, E. GROMACS 4.5: a high-throughput and highly parallel open source molecular simulation toolkit. Bioinformatics 2013, 29, 845−854. (76) Koziara, K. B.; Stroet, M.; Malde, A. K.; Mark, A. E. Testing and validation of the Automated Topology Builder (ATB) version 2.0: prediction of hydration free enthalpies. J. Comput.-Aided Mol. Des. 2014, 28, 221−233. (77) Rodríguez, A.; Espejo, Á . J.; Hernández, A.; Velásquez, O. L.; Lizaraso, L. M.; Cordoba, H. A.; Sánchez, O. F.; Alméciga-Díaz, C. J.; Barrera, L. A. Enzyme replacement therapy for Morquio A: an active recombinant N-acetylgalactosamine-6-sulfate sulfatase produced in Escherichia coli BL21. J. Ind. Microbiol. Biotechnol. 2010, 37, 1193− 1201. (78) Speir, M. L.; Zweig, A.; Villarreal, C.; Tyner, C.; Speir, M. L.; Rosenbloom, K.; Raney, B.; Lee, C.; Lee, B.; Karolchik, D.; Hinrichs, A.; Haeussler, M.; Guruvadoo, L.; Navarro, G. J.; Gibson, D.; Fiddes, I.; Eisenhart, C.; Diekhans, M.; Clawson, H.; Barber, G.; Armstrong, J.; Haussler, D.; Kuhn, R.; Kent, W. The UCSC Genome Browser database: 2018 update. Nucleic Acids Res. 2016, 44, D762−D769. (79) Adzhubei, I. A.; Schmidt, S.; Peshkin, L.; Ramensky, V. E.; Gerasimova, A.; Bork, P.; Kondrashov, A. S.; Sunyaev, S. R. A method and server for predicting damaging missense mutations. Nat. Methods 2010, 7, 248−249. (80) Choi, Y.; Sims, G. E.; Murphy, S.; Miller, J. R.; Chan, A. P. Predicting the functional effect of amino acid substitutions and indels. PLoS One 2012, 7, e46688−46621. (81) Pettersen, E. F.; Goddard, T. D.; Huang, C. C.; Couch, G. S.; Greenblatt, D. M.; Meng, E. C.; Ferrin, T. E. UCSF Chimera–a visualization system for exploratory research and analysis. J. Comput. Chem. 2004, 25, 1605−1612.

(82) Yang, J.; Yan, R.; Roy, A.; Xu, D.; Poisson, J.; Zhang, Y. The ITASSER Suite: protein structure and function prediction. Nat. Methods 2015, 12, 7−8. (83) Krieger, E.; Vriend, G. YASARA View - molecular graphics for all devices - from smartphones to workstations. Bioinformatics 2014, 30, 2981−2982. (84) Schneider, C. A.; Rasband, W. S.; Eliceiri, K. W. NIH Image to ImageJ: 25 years of image analysis. Nat. Methods 2012, 9, 671−675. (85) Huynh, K.; Partch, C. L. Analysis of protein stability and ligand interactions by thermal shift assay. Curr. Protoc. Protein Sci. 2015, 79, 28.9.1−28.9.14. (86) Ullal, A. J.; Millington, D. S.; Bali, D. S. Development of a fluorometric microtiter plate based enzyme assay for MPS IVA (Morquio type A) using dried blood spots. Mol. Genet. Metab. Rep. 2014, 1, 461−464.

6189


Identification of ezetimibe and pranlukast as pharmacological

Recommend Documents